Primary hyperaldosteronism caused by the excess production of ALDOSTERONE by an ADENOMA of the ZONA GLOMERULOSA or CONN ADENOMA.
| Excerpt | Reference |
|---|
| "Hyperaldosteronism is dependent on the maintenance of prostaglandin synthesis." | ( Spät, A; Tarján, E; Tóth, G, 1979) |
| "Hypoaldosteronism is more than the rare occurrence associated with Addison's disease." | ( Biglieri, EG, 1976) |
| "The recognition of Conn's syndrome is important for that account as it coincides with an operatively curable hypertension." | ( Bellin, H; Naumann, G; Schultz, J, 1975) |
| "Hyperaldosteronism is associated with hypertension, potassium depletion, and suppressed plasma renin activity." | ( Melby, JC, 1991) |
| "Primary aldosteronism is the principal disorder of the zona glomerulosa, and a number of subsets have been identified: unilateral adenoma, bilateral micro- or macronodular hyperplasia (idiopathic aldosteronism), primary hyperplasia, and aldosterone-producing carcinoma, either adrenal or ectopic." | ( Armanini, D; Biason, A; Boscaro, M; Carpenè, G; Fallo, F; Mantero, F; Opocher, G; Rocco, S; Scaroni, C; Sonino, N, 1990) |
| "Primary aldosteronism is an uncommon cause of hypertension but one of particular interest because of its distinctive pathophysiological mechanism of blood pressure elevation." | ( Fineberg, NS; Smith, JB; Wade, MB; Weinberger, MH, 1988) |
| "The diagnosis of primary hyperaldosteronism is only excluded adequately by the demonstration of suppression of aldosterone secretion." | ( Kincaid-Smith, P; Murphy, BF; Whitworth, JA, 1985) |
| "Primary aldosteronism is a potentially curable cause of hypertension; it occurs in about 1% of hypertensive patients." | ( Almog, C; Burke, M; Papo, J; Stavorovsky, M, 1984) |
| "Hyperaldosteronism is an important factor contributing to fluid and sodium retention in infants with heart failure." | ( Baylen, BG; Johnson, G; Kaplan, S; Srivastava, L; Tsang, R, 1980) |
| "A pseudo-primary aldosteronism is caused by the exogenic supply of mineralocorticoid-effective substances." | ( Lüscher, T; Siegenthaler, W, 1980) |
| "Primary aldosteronism is the commonest cause of potentially curable hypertension when diagnosed in both florid and less florid forms." | ( Gordon, RD; Klemm, SA; Stowasser, M; Tunny, TJ, 1995) |
| "Primary aldosteronism is an important, potentially curable, form of hypertension." | ( Ballantine, DM; Gordon, RD; Jonsson, JR; Klemm, SA; Stowasser, M; Tunny, TJ, 1994) |
| "A case of primary aldosteronism is presented in which the CT scan was initially misleading, adrenocortical scintigraphy was rendered inaccurate by pharmacological interference of spironolactone, and selective adrenal venous sampling of aldosterone was technically difficult." | ( Freitas, JE; Grekin, R; Gross, MD; Shapiro, B, 1994) |
| "Once primary aldosteronism is confirmed, localization by adrenal vein sampling, adrenal venography and adrenal computerized tomography is most effective in directing antihypertensive therapy." | ( Bihrle, R; Donohue, JP; Dugan, J; Eller, D; Gleason, PE; Pratt, JH; Weinberger, MH, 1993) |
| "Although primary hyperaldosteronism is an uncommon cause of hypertension, it is the most common form of renin-independent hypermineralocorticoidism." | ( Bonifacio, V; Ciampani, T; Giannini, D; Mancini, G; Sanna, AL, 1996) |
| "Primary hyperaldosteronism is an uncommon disorder, and there are few reports of its occurrence and management in pregnancy." | ( Moore, F; Seely, EW; Solomon, CG; Thiet, M, 1996) |
| "Primary aldosteronism is a potentially curable cause of hypertension, especially when caused by an adrenal adenoma." | ( Gianchandani, RY; Grekin, RJ; Gross, MD; Quin, GA; Shapiro, B; Sisson, JC; Thompson, NW, 1996) |
| "Primary aldosteronism is one of the differential diagnosis of secondary hypertension." | ( Chen, LG; Lee, TI; Lin, HD; Liu, WY; Tang, KT; Wang, HC, 1997) |
| "Although primary aldosteronism is rare, especially during pregnancy, it should be always considered as one of etiologies of hypertension in pregnancy." | ( Fujiyama, S; Inada, M; Iwasaka, T; Maruyama, K; Masaki, H; Matsubara, H; Matsuda, T; Mori, Y; Nagata, T; Okada, S; Umeda, Y; Yonemoto, T, 1999) |
| "Normotensive primary hyperaldosteronism is exceedingly rare." | ( Ghulam, A; Jeunemaitre, X; Lefebvre, J; Provost, F; Ronci, N; Tabarin, A; Vantyghem, MC, 1999) |
| "Primary aldosteronism is associated with hypertension secondary to salt and water retention, hypokalemia and impaired insulin secretion with glucose intolerance in some patients." | ( Bornstein, SR; Gordon, RD; Tauchnitz, R; Taylor, W; Torpy, DJ, 1999) |
| "Primary hyperaldosteronism is more frequent than previously thought, it is overlooked when hypokalemia is used as the screening test and it can only be diagnosed measuring plasma aldosterone and renin activity." | ( Fardella, C; Foradori, A; Huete, A; Montero, J; Mosso, L; Rojas, A; Rojas, P; Rojas, V; Sánchez, O; Soto, J, 1999) |
| "Primary hyperaldosteronism is characterized by high plasma and urinary aldosterone and suppressed PRA." | ( Bähr, V; Diederich, S; Oelkers, W, 2000) |
| "Primary hyperaldosteronism is more frequent among subjects with essential hypertension than previously thought." | ( Ahuad, J; Claverie, X; Cortés, P; Fardella, C; Foradori, A; Gac, H; Montero, J; Mosso, L; Oestreicher, E; Soto, J, 2000) |
| "The hypertension of Conn's syndrome is due to autonomous aldosterone production by a unilateral adrenocortical adenoma." | ( Connell, JM; Davies, E; Fraser, R; Friel, EC; Inglis, GC; Plouin, PF, 2001) |
| "When primary aldosteronism is diagnosed, fewer than one-third of patients are suitable for surgery as initial treatment, but this still represents a significant percentage of hypertensive patients." | ( Gordon, RD; Rutherford, JC; Stowasser, M, 2001) |
| "Primary aldosteronism is a common cause of non-renal secondary hypertension." | ( Benchetrit, S; Bernheim, J; Podjarny, E, 2002) |
| "Primary aldosteronism is classified as aldosterone-producing adenoma (APA), idiopathic hyperaldosteronism (IHA), unilateral adrenal hyperplasia (UAH), primary adrenal hyperplasia (PAH), adrenal cancer, and glucocorticoid-remediable aldosteronism." | ( Fujiwara, T; Nishikawa, T; Omura, M; Sasano, H; Yamaguchi, K, 2002) |
| "1." | ( Bobrie, G; Fiquet-Kempf, B; Launay-Mignot, P; Plouin, PF, 2001) |
| "Primary aldosteronism is a potentially curable form of hypertension." | ( Fardella, CE; Mosso, L, 2002) |
| "Primary aldosteronism is a disorder with hypertension, hypokalemia, increased plasma aldosterone, and suppressed renin activity." | ( Castro, OL; Kem, DC; Yu, X, 2002) |
| "Primary aldosteronism is a disorder that is commonly considered in patients referred to the hypertension clinic." | ( Arici, MH; Karimeddini, MK; Malchoff, CD; Mansoor, GA; Whalen, GF, 2002) |
| "Primary aldosteronism is a disorder characterized by hypertension and, in more severe form, hypokalemia, due to autonomous aldosterone secretion from the adrenocortical zona glomerulosa." | ( Jackson, RV; Lafferty, A; Stratakis, C; Torpy, DJ, 2002) |
| "Primary aldosteronism is a specifically treatable and potentially curable form of secondary hypertension." | ( Chiandussi, L; Milan, A; Morello, F; Mulatero, P; Paglieri, C; Rabbia, F; Veglio, F, 2002) |
| "Pseudohyperaldosteronism is characterized by a clinical picture of hyperaldosteronism with suppression of plasma renin activity and aldosterone." | ( Armanini, D; Calò, L; Semplicini, A, 2003) |
| "Thus, aldosteronism is associated with an activation of circulating immune cells induced by iterations in PBMC divalent cations and transduced by oxidative/nitrosative stress." | ( Ahokas, RA; Bhattacharya, SK; Gerling, IC; Herring, PA; Lu, L; Postlethwaite, AE; Sun, Y; Warrington, KJ; Weber, KT; Wodi, LA, 2003) |
| "Primary aldosteronism is the most common form of secondary hypertension." | ( Leotta, G; Morello, F; Mulatero, P; Rabbia, F; Veglio, F, 2003) |
| "Primary hyperaldosteronism is a well-recognized cause of secondary hypertension." | ( Benjamin, EJ; Evans, JC; Larson, MG; Levy, D; Meigs, JB; Rifai, N; Vasan, RS; Wilson, PW, 2004) |
| "Primary aldosteronism is a relatively common cause of secondary hypertension." | ( Hashimoto, S; Hayashi, M; Kuribayashi, S; Saruta, T; Sasamura, H; Takase, A; Ueno, K, 2004) |
| "Primary aldosteronism is a clinical syndrome characterized by hypokalemia, suppressed activities of plasma renin and high urinary and plasma aldosterone levels in hypertensive patients." | ( Kong, C; Li, Z; Wang, Y; Yang, C, 2004) |
| "Primary hyperaldosteronism is a diagnosis which should be considered in refractory hypertension even in the absence of any hypokalaemia." | ( Clementy, J; Gosse, P; Guiheneuf-Tobie, C; Lasserre, R; Lemetayer, P; Minifie, C, 2005) |
| "Primary aldosteronism is a rare cause of hypertension." | ( Bovy, C; Delanaye, P; Hamoir, E; Krzesinski, JM; Maweja, S; Radermecker, RP, 2005) |
| "Primary hyperaldosteronism is known to be frequently characterized by multiple adrenal lesions." | ( Arai, Y; Chiba, Y; Ishidoya, S; Ito, A; Sakai, K; Sato, F; Satoh, M, 2005) |
| "Primary hyperaldosteronism is highly associated with multiple adrenal space occupying lesions." | ( Arai, Y; Chiba, Y; Ishidoya, S; Ito, A; Sakai, K; Sato, F; Satoh, M, 2005) |
| "Primary hyperaldosteronism is much more frequent than was previously suspected." | ( Corrocher, R; Girelli, D; Guarini, P; Olivieri, O; Pavan, C; Pizzolo, F; Trabetti, E, 2005) |
| "Primary hyperaldosteronism is a frequently neglected cause of residual hypertension despite technically successful endovascular treatment of renal artery disease." | ( Corrocher, R; Girelli, D; Guarini, P; Olivieri, O; Pavan, C; Pizzolo, F; Trabetti, E, 2005) |
| "Although primary aldosteronism is a rare occurrence in children, the condition appears to deserve special attention not only from the viewpoint of growth failure and hypokalaemia but from the occurrence of late organ damage to the kidney and heart." | ( Higashino, H; Hirose, Y; Isozaki, Y; Kobayashi, Y; Noda, Y; Takaya, J, 2005) |
| "Primary aldosteronism is an important and one of the few potentially curable forms of secondary hypertension." | ( Kann, PH; Klein, HH; Roggenland, D; Schneider, S, 2006) |
| "Primary aldosteronism is the most common form of mineralocorticoid hypertension." | ( Dabasi, G; Füto, L; Gláz, E; Horányi, J; Jakab, C; Járay, J; Kiss, R; Major, L; Molnár, F; Patócs, A; Perner, F; Rácz, K; Szücs, N; Tóth, M; Tulassay, Z; Varga, I, 2006) |
| "Primary aldosteronism is a much more common cause of secondary hypertension than once suspected, accounting for approximately 10% of cases." | ( Bouloux, PM; Janmohamed, S, 2006) |
| "Primary aldosteronism is the most common endocrine form of secondary hypertension, but no single test or imaging method always identifies it." | ( Bernante, P; Pelizzo, MR; Rossi, GP; Toniato, A, 2006) |
| "The prevalence of primary hyperaldosteronism is 5-10% of all hypertensive patients, and clearly above the estimated prevalence in the past." | ( Quinkler, M; Reincke, M, 2006) |
| "Primary aldosteronism is caused by bilateral idiopathic hyperplasia in approximately two-thirds of cases and aldosterone-producing adenoma in one-third." | ( Mattsson, C; Young, WF, 2006) |
| "Primary hyperaldosteronism is a rare (<1%) and underdiagnosed cause of secondary hypertension." | ( Ahmed, SH; Husain, NM; Khawaja, SN; Massey, CV; Pettyjohn, FS, 2007) |
| "Primary hyperaldosteronism is the most common secondary form of hypertension." | ( Bidlingmaier, M; Diederich, S; Quinkler, M; Reincke, M, 2007) |
| "Primary hyperaldosteronism is described in a 27-year-old Brazilian woman from an endemic area of schistosomiasis." | ( Costa, AF; dos Santos, VM; Resurreição, FM; Vieira, MT, 2007) |
| "Primary hyperaldosteronism is not as uncommon as previously thought, but its prevalence depends on the selected population." | ( Tamimi, NA, 2007) |
| "Primary aldosteronism is a relatively common form of secondary hypertension -- affecting 5 to 10% of all patients with hypertension." | ( Young, WF, 2007) |
| "Primary aldosteronism is one of the few potentially curable forms of hypertension." | ( Auchus, RJ; Nwariaku, FE, 2007) |
| "Primary aldosteronism is recognized as the most frequent cause of secondary hypertension." | ( Corrocher, R; Olivieri, O; Pavan, C; Pizzolo, F, 2007) |
| "Hyperaldosteronism is now recognized as the most common secondary cause and all patients with resistant hypertension should be screened with a plasma aldosterone-renin ratio even if the serum potassium level is normal." | ( Calhoun, DA; Pimenta, E, 2007) |
| "Primary aldosteronism is associated with a cardiovascular complication rate out of proportion to blood pressure levels that benefits substantially from surgical and medical treatment in the long term." | ( Baroselli, S; Catena, C; Chiuch, A; Colussi, G; Lapenna, R; Nadalini, E; Sechi, LA, 2008) |
| "Hyperaldosteronism is associated with hypertension, cardiovascular fibrosis, and electrolyte disturbances, including hypomagnesemia." | ( Montezano, AC; Paravicini, T; Sontia, B; Tabet, F; Touyz, RM, 2008) |
| "1." | ( Amar, L; Plouin, PF; Rossignol, P, 2008) |
| "Primary aldosteronism is a leading cause of secondary hypertension (HTN), but the mechanisms underlying the characteristic renin-independent secretion of aldosterone remain unknown in most patients." | ( Geller, DS; Kashgarian, M; Lifton, RP; Shackleton, C; Wisgerhof, MV; Zhang, J, 2008) |
| "Hyperaldosteronism is associated with endothelial dysfunction and impaired vascular reactivity in patients with hypertension or congestive heart failure." | ( Leopold, JA; Maron, BA, 2008) |
| "Primary aldosteronism is the most common cause of mineralocorticoid-induced hypertension, and MR antagonism offers the best prospect for achieving therapeutic goals." | ( Nagata, K, 2008) |
| "Primary aldosteronism is increasingly investigated in hypertension being associated with an elevated cardiovascular risk." | ( Di Cecco, P; Fommei, E; Ghione, S; Iervasi, A; Maffei, S; Ripoli, A; Turchi, S, 2009) |
| "Hyperaldosteronism is associated with impaired endothelium-dependent vascular reactivity owing to increased reactive oxygen species and decreased bioavailable nitric oxide (NO(." | ( Beuve, A; Handy, DE; Leopold, JA; Loscalzo, J; Maron, BA; Tang, SS; Zhang, YY, 2009) |
| "Features of hyperaldosteronism are also found in patients with apparent mineralocorticoid excess (AME), in which glucocorticoids exacerbate activation of the mineralocorticoid receptor (MR) because of a defect in the 11beta-hydroxysteroid dehydrogenase type 2 enzyme." | ( Escher, G, 2009) |
| "Primary aldosteronism is caused by autonomous secretion of aldosterone by the adrenal cortex which results in hypertension with clinically, biochemically and therapeutically distinct features." | ( Beuschlein, F, 2009) |
| "Primary hyperaldosteronism is a growing cause of apparently essential hypertension (until 15 % of patients with hypertension)." | ( Carnaille, B; Douillard, C; Mounier-Vehier, C; Wémeau, JL, 2009) |
| "Primary aldosteronism is common among patients with resistant hypertension, as is obstructive sleep apnea." | ( Acelajado, MC; Calhoun, DA, 2009) |
| "Primary aldosteronism is the most common form." | ( Ibsen, H; Poulsen, PL, 2009) |
| "Primary hyperaldosteronism is the most common curable cause of hypertension with a prevalence of up to 12% among patients with hypertension." | ( Georgiades, C; Hong, K; Kharlip, J; Valdeig, S; Wacker, FK, 2009) |
| "Aldosteronism is considered as part of this disorder." | ( Abdallah, Y; Schlüter, KD; Schreckenberg, R; Tastan, I; Wenzel, S, 2010) |
| "Primary hyperaldosteronism is characterised by hypertension, hypokalemia, suppressed plasma renin activity, and increased aldosterone excretion." | ( Corrales, PP; López, AH; Martínez, JJ; Meneses, AL; Oliveira, CL; Rodríguez, SA; Romero, FB, 2009) |
| "Primary aldosteronism is considered the most prevalent form of secondary hypertension with pathophysiological and clinical features different from those of essential hypertension." | ( Beuschlein, F, 2010) |
| "Primary aldosteronism is the most common form of secondary hypertension and patients with hyperaldosteronism are more prone to premature cardiovascular complications compared to essential hypertensives." | ( Bertello, C; Iannaccone, A; Mengozzi, G; Monticone, S; Mulatero, P; Tizzani, D; Veglio, F, 2010) |
| "Hyperaldosteronism is associated with vascular injury and increased cardiovascular events." | ( Bauersachs, J; Dietrich, B; Ertl, G; Fleissner, F; Hahner, S; Jazbutyte, V; Schmitter, K; Thum, T; Widder, JD; Wiebking, V, 2011) |
| "Primary aldosteronism is the most common form of secondary hypertension with hypokalemia and suppressed renin-angiotensin system caused by autonomous aldosterone production." | ( Amar, L; Benecke, A; Boulkroun, S; Dzib, JF; Jeunemaitre, X; Lalli, E; Lefebvre, H; Louiset, E; Meatchi, T; Plouin, PF; Samson-Couterie, B; Zennaro, MC, 2010) |
| "Because primary aldosteronism is not uncommon, specifically treatable and in some cases curable, and carries higher risks for cardiovascular morbidity and mortality than essential hypertension, screening hypertensive patients for its presence by measuring aldosterone to renin ratio (ARR) is increasingly common." | ( Ahmed, AH; Gordon, RD; Pimenta, E; Stowasser, M; Taylor, PJ; Ward, G, 2011) |
| "Primary aldosteronism is considered to be responsible for almost 10% of all cases of arterial hypertension." | ( Beuschlein, F; Bidlingmaier, M; Gomez-Sanchez, C; Hrabé de Angelis, M; Manolopoulou, J; Rathkolb, B; Reincke, M; Spyroglou, A; Wagner, S; Wolf, E, 2011) |
| "Primary aldosteronism is more common than previously recognized but much less common than most experts in this arena have recently stated." | ( Kaplan, NM, 2010) |
| "Primary aldosteronism is the most frequent cause of secondary hypertension and is responsible for an increased risk of cardiometabolic complications." | ( Bertello, C; Boulkroun, S; Fallo, F; Fassina, A; Monticone, S; Mulatero, P; Sonino, N; Tizzani, D; Veglio, F; Viola, A, 2011) |
| "Hyperaldosteronism is associated with an increased prevalence of atrial fibrillation (AF)." | ( Allessie, MA; Böhm, M; Drautz, F; Hohl, M; Kazakow, A; Lipp, P; Müller, P; Münz, BM; Neuberger, HR; Reil, GH; Reil, JC; Selejan, S; Steendijk, P, 2012) |
| "Primary aldosteronism is one of several potentially reversible causes of resistant hypertension." | ( Sica, DA, 2011) |
| "Primary aldosteronism is the most common form of secondary hypertension." | ( Allolio, B; Amar, L; Benecke, A; Beuschlein, F; Boulkroun, S; Ceolotto, G; Cicala, MV; Fallo, F; Fischer, E; Golib-Dzib, JF; Hahner, S; Jeunemaitre, X; Lang, K; Lefebvre, H; Lenzini, L; Letizia, C; Maniero, C; Mantero, F; Monticone, S; Mulatero, P; Perrocheau, M; Pilon, C; Plouin, PF; Quinkler, M; Rayes, N; Reincke, M; Rossi, GP; Samson-Couterie, B; Seccia, TM; Veglio, F; Williams, TA; Zennaro, MC; Zinnamosca, L, 2012) |
| "Primary hyperaldosteronism is reported to facilitate urinary calcium excretion; however, renal calculi or calcinosis in this disorder has been rarely reported." | ( Hayashi, T; Isaka, Y; Rakugi, H; Sasaki, K; Yamato, M; Yasuda, K, 2012) |
| "Primary aldosteronism is the most frequent cause of secondary hypertension and is associated with more prominent left ventricular hypertrophy and increased myocardial fibrosis." | ( Chang, HW; Chueh, SC; Ho, YL; Lee, HH; Lee, JK; Lin, CY; Lin, LC; Lin, YH; Liu, YC; Lo, MT; Wu, KD; Wu, VC; Wu, XM, 2012) |
| "Primary hyperaldosteronism is most commonly due to a solitary cortical adenoma." | ( Abraham, SB; Barak, S; Kebebew, E; Mathur, A; Nilubol, N; Quezado, M; Stratakis, CA; Webb, RC; Weisbrod, AB, 2013) |
| "Primary hyperaldosteronism is the most common cause of secondary hypertension." | ( Abad-Cardiel, M; Alvarez-Álvarez, B; Fernández, C; Fernández-Cruz, A; Luque-Fernandez, L; Martell-Claros, N, 2013) |
| "Primary aldosteronism is characterised by the dysregulation of aldosterone production and comprises both sporadic forms, caused by an aldosterone-producing adenoma or bilateral adrenal hyperplasia, and familial forms (familial hyperaldosteronism types I, II and III)." | ( Monticone, S; Mulatero, P; Rainey, WE; Veglio, F; Williams, TA, 2013) |
| "Primary aldosteronism is a major cause of secondary hypertension worldwide." | ( Lifton, RP; Scholl, UI, 2013) |
| "Primary aldosteronism is common, and when unrecognized is associated with an increased incidence of adverse cardiovascular outcomes." | ( Weiner, ID, 2013) |
| "Primary aldosteronism is the commonest form of hormone-related hypertension, with an estimated prevalence of 6-13% in the generalpopulation of hypertensive patients." | ( Januszewicz, A; Januszewicz, W; Kołodziejczyk-Kruk, S; Pęczkowska, M; Prejbisz, A; Zgliczyński, W, 2013) |
| "Primary aldosteronism is a heterogeneous group of disorders comprising both sporadic and familial forms." | ( Edwards, MA; Hattangady, NG; Isales, CM; Monticone, S; Mulatero, P; Penton, D; Rainey, WE; Sterner, C; Warth, R; Williams, TA, 2013) |
| "Primary aldosteronism is the most common form of secondary hypertension and has significant cardiovascular consequences." | ( Gomez-Sanchez, CE; Oki, K, 2014) |
| "Primary aldosteronism is the most common form of secondary hypertension." | ( Allolio, B; Amar, L; Bernini, G; Beuschlein, F; Boulkroun, S; Cicala, MV; Fallo, F; Fernandes-Rosa, FL; Giacchetti, G; Jeunemaitre, X; Maccario, M; Mantero, F; Meatchi, T; Monticone, S; Mulatero, P; Quinkler, M; Reincke, M; Riester, A; Steichen, O; Strom, TM; Williams, TA; Zennaro, MC, 2014) |
| "Refractory hyperaldosteronism is frequently observed in heart failure patients on up-to-date treatment, and holds prognostic value." | ( Abbate, R; Emdin, M; Fatini, C; Gensini, G; Passino, C; Ripoli, A; Rossignol, P; Sticchi, E; Vassalle, C; Vergaro, G, 2015) |
| "Primary aldosteronism is the most frequent endocrine cause of secondary hypertension." | ( Abad-Cardiel, M; Alvarez-Alvarez, B; García-Donaire, JA; Martell-Claros, N; Pérez, CF, 2015) |
| "Primary aldosteronism is increasingly recognized as a common secondary cause of hypertension." | ( Brown, MJ; Gurnell, M; Powlson, AS, 2015) |
| "Primary hyperaldosteronism is an increasingly recognized syndrome in cats, and diagnosis can be difficult." | ( Behrend, EN; Johnson, A; Kemppainen, R; Lee, H; Matsuda, M; Refsal, K, 2015) |
| "Primary aldosteronism is one of the commonly identified causes of hypertension and is treatable and/or potentially curable." | ( Ardhanari, S; Chaudhary, K; Kannuswamy, R; Lockette, W; Whaley-Connell, A, 2015) |
| "Although primary aldosteronism is associated with more prominent cardiac remodeling and diastolic dysfunction, the reversibility of diastolic function is unclear." | ( Chang, YS; Chang, YY; Chen, MF; Chen, YH; Chou, CH; Ho, YL; Hung, CS; Lin, YH; Su, MJ; Tsai, YC; Wu, KD; Wu, VC; Wu, XM, 2015) |
| "Primary hyperaldosteronism is a common cause of hypertension, with significant cardiovascular, renal, and metabolic sequelae." | ( Fraker, DL; Kelz, RR; Kuo, LE; Roses, RE; Wachtel, H, 2015) |
| "Primary aldosteronism is the most common form of secondary hypertension." | ( Amar, L; Boulkroun, S; Fernandes-Rosa, FL; Giscos-Douriez, I; Gomez-Sanchez, CE; Meatchi, T; Zennaro, MC, 2015) |
| "Primary hyperaldosteronism is a specifically treatable and potentially curable form of hypertension, which typically presents as drug-resistant hypertension and, in up to 37% of cases, hypokalemia." | ( Fong, BM; Siu, TS; Tam, S, 2015) |
| "Primary aldosteronism is characterized by hypertension, suppressed plasma renin activity, increased aldosterone excretion and hypokalemia with metabolic alkalosis." | ( Concistrè, A; Fiacco, F; Letizia, C; Marinelli, C; Mitterhofer, AP; Petramala, L; Tinti, F; Umbro, I; Zavatto, A; Zingaretti, V, 2015) |
| "Primary aldosteronism is the cause of hypertension in 5-10% of the hypertensive population." | ( Johannsson, G; Muth, A; Ragnarsson, O; Sakinis, A; Wängberg, B, 2015) |
| "Primary aldosteronism is one of the most common forms of secondary hypertension, but it is often under diagnosed, which leads to the development of cardiovascular damage, and excess costs for long-term drug treatment and management of complications." | ( Bisogni, V; Rossi, GP, 2016) |
| "Hyperaldosteronism is associated with an increased prevalence of atrial fibrillation (AF)." | ( Buschmeyer, B; Koehncke, C; Lisewski, U; Pieske, B; Roepke, TK; Wilck, N, 2016) |
| "Normotensive hyperaldosteronism is a rare disorder." | ( Amirbaigloo, A; Moradi, S; Shafiepour, M, 2016) |
| "Primary aldosteronism is associated with increased left ventricular (LV) mass independently of blood pressure." | ( Bertin, N; Catena, C; Colussi, G; Novello, M; Pilz, S; Sechi, LA; Tomaschitz, A; Verheyen, ND, 2016) |
| "Pseudohyperaldosteronism is characterized by a clinical picture of hyperaldosteronism with suppression of renin and aldosterone." | ( Armanini, D; Sabbadin, C, 2016) |
| "Primary aldosteronism is the most common form of secondary hypertension and affects 8-13% of patients with hypertension." | ( Dutta, RK; Gimm, O; Söderkvist, P, 2016) |
| "Primary aldosteronism is present in ≈10% of hypertensives." | ( Azizan, EA; Brown, MJ; Lam, B; Neogi, SG; Yeo, GS; Zhou, J, 2016) |
| "Primary aldosteronism is one of the most common causes of secondary hypertension." | ( Ambroziak, U; Bednarczuk, T; Gałązka, Z; Hoffmann, M; Janaszek-Sitkowska, H; Januszewicz, A; Januszewicz, M; Kabat, M; Kądziela, J; Kołodziejczyk-Kruk, S; Michałowska, I; Prejbisz, A; Ptasińska-Wnuk, D; Schultze Kool, L; Toutounchi, S; Witkowski, A, 2017) |
| "Hyperaldosteronism is the leading cause of secondary hypertension with up to 80% due to APA, statistically the most common functioning adrenal nodule." | ( Faintuch, S; Sacks, AC; Sacks, BA, 2017) |
| "Primary aldosteronism is characterized by excess aldosterone (ALDO) secretion independent of the renin-angiotensin system and accounts for approximately 10% of hypertension cases." | ( Ball, JP; Hall, ME; Kc, R; Marañon, RO; Reckelhoff, JF; Romero, DG; Syed, M; Yanes Cardozo, LL, 2017) |
| "Primary aldosteronism is a common cause of hypertension, which becomes refractory if undiagnosed, but potentially curable when caused by an aldosterone-producing adenoma (APA)." | ( Brown, MJ; Garg, S; Gomez-Sanchez, CE; Gurnell, M; Johnson, TI; Teo, AE; Zhao, W; Zhou, J, 2017) |
| "Primary hyperaldosteronism is a common cause of hypertension in the adult population." | ( Carroll, R; Feltham, J; Gould, A; Harper, S, 2017) |
| "Conn's Syndrome is an uncommon condition." | ( Christakis, I; Graham, P; Grubbs, EG; Julien, JS; Lee, JE; Perrier, ND; Schwarz, K; Starker, LF, 2017) |
| "Primary aldosteronism is associated with a higher incidence of left ventricular (LV) hypertrophy and diastolic dysfunction than essential hypertension." | ( Chang, YY; Chen, CW; Chen, ZW; Huang, KC; Hung, CS; Lee, JK; Liao, CW; Lin, LC; Lin, YH; Wu, VC, 2018) |
| "Primary aldosteronism is recognized as a severe form of renin-independent aldosteronism that results in excessive mineralocorticoid receptor (MR) activation." | ( Allison, MA; Baudrand, R; Brown, JM; de Boer, IH; Ix, JH; Kestenbaum, B; Luque-Fernandez, MA; Robinson-Cohen, C; Vaidya, A, 2017) |
| "Primary hyperaldosteronism is an adrenal abnormality in which there is some degree of autonomy of aldosterone secretion." | ( Amarwati, S; Naibaho, R; Pemayun, TGD; Santosa, A; Wiyati, MW, 2017) |
| "Primary aldosteronism is the most common type of secondary hypertension affecting 6-10% of patients with primary hypertension." | ( Gomez-Sanchez, CE; Kuppusamy, M; Reincke, M; Williams, TA, 2017) |
| "Primary aldosteronism is the most common form of secondary hypertension." | ( Boulkroun, S; Fernandes-Rosa, FL; Zennaro, MC, 2018) |
| "Primary aldosteronism is the most common form of endocrine hypertension with a prevalence of 6% in the general population with hypertension." | ( Aristizabal Prada, ET; Beuschlein, F; Castellano, I; Meyer, LS; Reincke, M; Sušnik, E; Tetti, M; Williams, TA; Yang, Y, 2018) |
| "Primary aldosteronism is affecting about 10% of hypertensive patients." | ( Amar, L; Azizi, M; Baffalie, L; Baron, S; Blanchard, A; Faucard, C; Faucon, AL; Houillier, P; Pagny, JY; Travers, S, 2018) |
| "Primary aldosteronism is associated with high cardiovascular morbidity and mortality due to activation of cardiac mineralocorticoid receptors." | ( Alvarez, C; Mohan, V, 2018) |
| "Unilateral primary aldosteronism is the most common surgically correctable form of endocrine hypertension and is usually differentiated from bilateral forms by adrenal venous sampling (AVS) or computed tomography (CT)." | ( Adolf, C; Baudrand, R; Bernardi, S; Beuschlein, F; Burrello, J; Catena, C; Douma, S; Doumas, M; Fallo, F; Fardella, CE; Giacchetti, G; Hahner, S; Heinrich, DA; Jansen, PM; Januszewicz, A; Kocjan, T; Matrozova, J; Mulatero, P; Nishikawa, T; Quinkler, M; Reincke, M; Saint-Hilary, G; Satoh, F; Sechi, LA; Stowasser, M; Umakoshi, H; Widimský, J; Williams, TA, 2018) |
| "Primary aldosteronism is characterized by excess aldosterone secretion by the adrenal gland independent of the renin-angiotensin system and accounts for ~10% of hypertensive patients." | ( Ball, JP; Hall, ME; Mathis, KW; Romero, DG; Rothenberg, ME; Ryan, MJ; Syed, M; Yanes Cardozo, LL, 2018) |
| "Unilateral primary aldosteronism is surgically curable." | ( Bhandari, S; Cohen, DL; Fraker, DL; Roses, RE; Trerotola, SO; Wachtel, H, 2019) |
| "Primary aldosteronism is one of the most common cause of secondary hypertension." | ( Aibara, Y; Chayama, K; Goto, C; Hashimoto, H; Higashi, Y; Kajikawa, M; Kihara, Y; Kishimoto, S; Liao, JK; Maruhashi, T; Matsui, S; Nakashima, A; Noma, K; Oki, K; Takaeko, Y; Yusoff, FM, 2019) |
| "Primary aldosteronism is a secondary hypertensive disease caused by autonomous aldosterone production that often caused by an aldosterone-producing adenoma (APA)." | ( Higashi, T; Kosaka, T; Mizuno, Y; Nishikawa, T; Nishimoto, K; Omura, M; Oya, M; Seki, T; Shimma, S; Suematsu, M; Sugiura, Y; Takeo, E; Yokota, M, 2018) |
| "Primary aldosteronism is a common cause of secondary hypertension." | ( Hamberger, B; Juhlin, CC; Volpe, C; Zedenius, J, 2020) |
| "Primary aldosteronism is the most common causes of secondary hypertension." | ( Doumas, M; Koutsampasopoulos, K; Lales, G; Mitas, C; Papadopoulos, C; Stavropoulos, K, 2018) |
| "Primary aldosteronism is characterized by inappropriate overproduction of aldosterone by adrenal lesions and leads to hypertension." | ( Ichihara, A; Morimoto, S; Seki, Y; Watanabe, D; Yamashita, K, 2019) |
| "Primary aldosteronism is a common cause of secondary hypertension." | ( Beninato, T; Fahey, TJ; Sivarajah, M, 2020) |
| "Primary aldosteronism is recognized as the most frequent cause of secondary hypertension, and its screening is expected to become a routine evaluation in most patients with hypertension." | ( Buffolo, F; Burrello, J; Domenig, O; Monticone, S; Mulatero, P; Pecori, A; Poglitsch, M; Tetti, M, 2020) |
| "Primary aldosteronism is currently considered to represent 5-13% of hypertension, yet fewer than 1% of patients with the disorder are ever diagnosed and treated." | ( Funder, J, 2020) |
| "Primary aldosteronism is a nonsuppressible renin-independent aldosterone production that causes hypertension and cardiovascular disease." | ( Brown, JM; Calhoun, DA; Carey, RM; Hopkins, PN; Siddiqui, M; Vaidya, A; Williams, GH, 2020) |
| "Hyperaldosteronism is suggested to cause inflammation and metabolic dysregulation, and might contribute to CVD development in obese individuals." | ( Danser, AHJ; de Graaf, J; Deinum, J; Joosten, LAB; Netea, MG; Riksen, NP; Rutten, J; Schraa, K; Ter Horst, R; van den Munckhof, ICL; van der Heijden, CDCC, 2020) |
| "Primary aldosteronism is associated with higher cardiovascular and renal morbidity and mortality than essential hypertension in age- and sex-matched patients with the same degree of blood pressure elevation." | ( Araujo-Castro, M, 2020) |
| "Conn's syndrome is a curable condition if identified properly." | ( Alseddeeqi, E; Altinoz, A; Ghashir, NB, 2020) |
| "Primary aldosteronism is the most common form of secondary hypertension with a prevalence of 5-10% in hypertensive patients." | ( Gomez-Sanchez, CE; Oki, K, 2020) |
| "Primary hyperaldosteronism is a recognized risk factor for myocardial infarction, stroke, and atrial fibrillation." | ( Billeter, A; Billmann, F; El Shishtawi, S; Keck, T; Langan, EA; Müller-Stich, BP; Strobel, O; Thomusch, O, 2021) |
| "Primary aldosteronism is common and contributes to adverse cardiovascular, kidney, and metabolic outcomes." | ( Hundemer, GL; Vaidya, A, 2020) |
| "Primary aldosteronism is an underdiagnosed cause of hypertension." | ( Fudim, T; Hundemer, GL; Moussa, M; Sacks, B; Underhill, J; Vaidya, A; Yozamp, N, 2021) |
| "Hyperaldosteronism is tentatively classified into primary and secondary types." | ( Gao, X; Morimoto, R; Nakamura, Y; Omata, K; Ono, Y; Sasano, H; Satoh, F; Suzuki, T; Tezuka, Y; Yamazaki, Y, 2021) |
| "Primary aldosteronism is a common, yet highly underdiagnosed, cause of hypertension that leads to disproportionately high rates of cardiovascular disease." | ( Agharazii, M; Goupil, R; Hundemer, GL; Imsirovic, H; Knoll, G; Madore, F; Sood, MM; Vaidya, A; Yozamp, N, 2022) |
| "Hyperaldosteronism is a relatively more common disorder than previously recognized." | ( Arafah, BM; El-Asmar, N; Rajpal, A, 2021) |
| "Primary aldosteronism is the most common form of secondary hypertension, and aldosteronoma makes up a significant proportion of primary aldosteronism cases." | ( Dai, Y; Li, J; Liu, J; Wen, H, 2021) |
| "Primary aldosteronism is a common cause of secondary hypertension associated with excess cardiovascular morbidities." | ( Bancos, I; Mulatero, P; Reincke, M; Scholl, UI; Stowasser, M; Williams, TA, 2021) |
| "Primary aldosteronism is one of the most frequent causes of secondary arterial hypertension, and whether primary aldosteronism is associated with masked hypertension is unknown." | ( Bari, V; Barraclough, R; Graff, B; Hoffmann, M; Kanarek-Kucner, J; Narkiewicz, K, 2022) |
| "Primary aldosteronism is mainly caused by APAs or idiopathic hyperaldosteronism (IHA)." | ( Gomez-Sanchez, CE; Horiuchi, Y; Iwahashi, N; Kosaka, T; Mukai, K; Nishimoto, K; Ogawa, Y; Oya, M; Seki, M; Seki, T; Suematsu, M; Suzuki, Y; Umakoshi, H; Umezawa, Y, 2022) |
| "Primary aldosteronism is the most common surgically curable form of hypertension." | ( Gong, S; Reincke, M; Tetti, M; Veglio, F; Williams, TA, 2022) |
| "Primary aldosteronism is a common cause of hypertension and is a risk factor for cardiovascular and renal morbidity and mortality, via mechanisms mediated by both hypertension and direct insults to target organs." | ( Turcu, AF; Vaidya, A; Yang, J, 2022) |
| "Primary aldosteronism is the most common surgically curable cause of endocrine hypertension." | ( Fuller, PJ; Grodski, S; Lee, JC; Libianto, R; Shen, J; Yang, J; Zhang, J, 2022) |
| "Primary aldosteronism is now recognized as the most common cause of secondary hypertension." | ( Jin, HY; Kim, YJ; Lee, HW; Lee, KA, 2022) |
| "Primary aldosteronism is the most common cause of secondary hypertension." | ( Bischoff, C; Hayes, A; Morgan, B; Stowasser, M; Torpy, DJ; Umapathysivam, MM; Wilks, M, 2023) |
| "Primary aldosteronism is the most common form of secondary arterial hypertension, due to excessive aldosterone production from the adrenal gland." | ( Abdellatif, AB; Boulkroun, S; Fernandes-Rosa, FL; Zennaro, MC, 2022) |
| "Primary aldosteronism is the most common form of secondary arterial hypertension, due to excessive aldosterone production from the adrenal gland." | ( Abdellatif, AB; Boulkroun, S; Fernandes-Rosa, FL; Zennaro, MC, 2022) |
| "Primary hyperaldosteronism is a major cause of secondary hypertension and carries additional cardiovascular risks beyond that of the elevated blood pressure." | ( Albert, SG; Bruno, J; Dhindsa, S; Ling, G, 2023) |
| "Primary aldosteronism is the most frequent secondary hypertensive disease and is characterized by an elevated risk for cardiovascular disease." | ( Fujiwara, A; Haruna, A; Haze, T; Hirawa, N; Kawano, R; Kobayashi, Y; Ohki, Y; Ozawa, M; Saka, S; Suzuki, S; Tamura, K, 2023) |
| "Primary aldosteronism is associated with an increased risk of cardiovascular disease and kidney dysfunction compared to essential hypertension." | ( Abe, M; Kobayashi, H; Otsuka, H, 2023) |
| "Primary hyperaldosteronism is the most common cause of secondary hypertension." | ( Hamoir, E; Wilmont, E, 2023) |
| "Primary aldosteronism is frequently caused by an adrenocortical aldosterone-producing adenoma (APA) carrying a somatic mutation that drives aldosterone overproduction." | ( Blum, H; Gong, S; Koupourtidou, C; Krebs, S; Masserdotti, G; Meyer, LS; Rainey, WE; Reincke, M; Sun, N; Tetti, M; Walch, A; Williams, TA, 2023) |
| "Primary aldosteronism is the most common single cause of hypertension and is potentially curable when only one adrenal gland is the culprit." | ( Azizan, EAB; Brown, MJ; Drake, WM, 2023) |
| "Primary aldosteronism is the underlying cause of hypertension in primary care settings in approximately 6% of cases, and it is even more common in patients with resistant hypertension." | ( Quencer, KB; Rugge, JB; Senashova, O, 2023) |
| Excerpt | Reference |
|---|
| "In a patient suffering from Conn's syndrome analysis of short-time fluctuations of plasma aldosterone, plasma cortisol and plasma renin activity were performed before and after a 9-months therapy period with spironolactone." | ( Vetter, H; Vetter, W, 1975) |
| "Diabetic patients with hypoaldosteronism have the potential for severe hyperkalemia should renal or extrarenal mechanisms for potassium homeostasis be challenged by severe acidosis be challenged by severe acidosis, diminished renal function, marked hyperglycemia, or administration of potassium salts or potassium-sparing diuretics." | ( Knowles, R; Lespier, L; Oster, JR; Perez, GO; Vaamonde, CA, 1977) |
| "(4) Far above other mechanism hyperaldosteronism is most often induced by saluretic treatment of ascites and edema." | ( Spech, HJ, 1979) |
| "The mechanism of diuretic-induced hyperaldosteronism was examined in dexamethasone-pretreated rats." | ( Spät, A; Tarján, E; Tóth, G, 1979) |
| "Secondary hyperaldosteronism as seen in 11 patients without spironolactone-therapy after surgery did not persist very long." | ( Holzer, H; Parth, K; Wimmer, M, 1979) |
| "In primary aldosteronism, urinary kallikrein showed moderate decrease after the spironolactone treatment from 8." | ( Abe, K; Chiba, S; Irokawa, N; Otsuka, Y; Sakurai, Y; Seino, M; Yasujima, M; Yoshinaga, K, 1977) |
| "Five patients with primary aldosteronism due to adenoma were followed during spironolactone treatment, for 35-55 days after the drug had been stopped, and finally, after surgery." | ( Derkx, FH; Man in 't Veld, AJ; Schalekamp, DH; Verhoeven, RP; Wenting, GH, 1977) |
| "In primary aldosteronism due to an adrenal adenoma (n=2), treatment with a spirolactone (160 mg Canrenone/day for 7 days) decreased plasma aldosterone and urinary aldosterone-18-glucuronide." | ( Appenheimer, M; Glänzer, K; Herschbach, ML; Krück, F; Lucas, R; Vetter, H; Weiand, H; Witassek, F, 1977) |
| "Twenty-eight patients with primary aldosteronism were treated from 1974 to 1990." | ( Wang, GY, 1992) |
| "A case of primary aldosteronism treated with spironolactone therapy has been followed up for 24 years." | ( Hashimoto, T; Ito, Y; Koshida, H; Miyamori, I; Morimoto, S; Morise, T; Takeda, R; Yamazaki, T, 1992) |
| "Four patients with primary hyperaldosteronism were treated with nadroparin 4100 or 6150 antiXa IU daily for 4 days." | ( Cailleux, N; Courtois, H; Godin, M; Levesque, H; Moore, N, 1992) |
| "This case of Conn's syndrome demonstrates long-term (seven years) efficacy of triamterene-thiazide therapy in controlling both hypertension and hypokalemia." | ( Bornemann, M, 1990) |
| "Dexamethasone-suppressible hyperaldosteronism (DSH) is a rare familial variety of primary aldosteronism in which the biochemical features of mineralocorticoid excess are corrected by treatment with glucocorticoids." | ( Burns, A; Murnaghan, DJ; O'Mahony, S, 1989) |
| "Four patients with idiopathic aldosteronism all had an increase in plasma aldosterone levels after 5HTP administration, whereas the response in four patients with aldosterone-producing adenoma was variable." | ( Grekin, RJ; Gross, MD; Shenker, Y, 1985) |
| "Dexamethasone-suppressible hyperaldosteronism is a rare familial syndrome in which hypokalemia, suppression of plasma renin concentration, and elevated aldosterone secretion are corrected by treatment with glucocorticoids." | ( Connell, JM; Corrie, JE; Fraser, R; Kenyon, CJ; Lever, AF; Watt, R, 1986) |
| "Three patients with idiopathic hyperaldosteronism were continuously treated with trilostane, a competitive inhibitor of adrenal 3 beta-hydroxysteroid dehydrogenase (3 beta-HSDH) (3 to 4 2/3 years)." | ( Demura, H; Horiba, N; Nomura, K; Shizume, K, 1986) |
| "Three patients with primary aldosteronism were treated surgically between February and September 1984." | ( Ejiri, S; Kojima, A; Okuda, K; Shoda, R; Sumitani, T, 1986) |
| "Six patients with primary aldosteronism (PA), one with idiopathic hyperaldosteronism (IHA), one with glucocorticoid responsible hyperaldosteronism (GRHA) and eight with essential hypertension (EH) were treated with trilostane (MWD-1822) (4 alpha, 5-epoxy-17 beta-hydroxy-3-oxo-5 alpha-androstane-2 alpha-carbonitrile), an inhibitor of adrenal steroid biosynthesis, for 9-47 days with a daily dose of 30-960 mg." | ( Fukuchi, S; Haruyama, K; Shigetomi, S; Yamazaki, M, 1982) |
| "In untreated patients with primary aldosteronism caused either by adrenal adenoma or hyperplasia plasma aldosterone and cortisol concentrations fluctuated in unison and dexamethasone reduced both hormones markedly." | ( Ganguly, A; Luetscher, JA; Weinberger, MH, 1982) |
| "Hyperaldosteronism was confirmed in 74% of 72 consecutive patients admitted for acute myocardial infarction, in 85% if patients previously treated by an antialdosterone drug or admitted after the acute phase are excluded, and in 96% if patients with cardiac failure are included." | ( Denis, B; Dimitriou, R; Machecourt, J; Page, E; Reboud, JP; Wolf, JE, 1984) |
| "A 58-year-old man with primary aldosteronism associated with chronic chronic renal failure was treated with CAPD, oral administrations of Trilostane and furosemide." | ( Katayama, T; Nakada, T, 1983) |
| "Thirty-four patients with untreated Conn's syndrome were studied in a metabolic ward." | ( Beretta-Piccoli, C; Brown, JJ; Davies, DL; Ferriss, B; Fraser, R; Lasaridis, A; Lever, AF; Morton, JJ; Robertson, JI; Semple, PF, 1983) |
| "Because hypertension in Conn's syndrome resistant to spironolactone usually also responds poorly to removal of the adenoma, and is difficult to treat with conventional hypotensive agents, the combination of a converting enzyme inhibitor with a potassium conserving diuretic is worthy of trial in such cases." | ( Atkinson, AB; Brown, JJ; Davies, DL; Lever, AF; Robertson, JI, 1981) |
| "Diagnosis and therapy of pseudo-hypoaldosteronism are discussed as well as the problems of long-term oral sodium chloride substitution and long-term therapy with sodium-polystyrol-sulfonate, a cation-exchange resin." | ( Herkner, K; Pollak, A; Popow, C; Schober, E; Waldhäusl, W, 1982) |
| "Primary aldosteronism, when caused by an aldosterone-producing adenoma, is a surgically treatable condition." | ( Hugo, JM; Shipton, EA, 1982) |
| "Secondary aldosteronism in connection with decompensated cirrhosis of the liver arises mainly under therapy with diuretics." | ( Albert, JP; Hartmann, F, 1981) |
| "Idiopathic aldosteronism was usually treated by unilateral or subtotal adrenalectomy." | ( Kumagai, A, 1980) |
| "We believe that primary hyperaldosteronism was a major pathogenetic factor in the formation of renal calculi since the increased urinary excretion of Ca++ and uric acid noted at onset declined following a short-term spironolactone administration and remission from renal calculi has persisted following initial nephrolithotomy and continued spironolactone therapy, which also corrected hypertension and hypokalemia, a hallmark of this disorder." | ( Kabadi, UM, 1995) |
| "Latent hypoaldosteronism probably predisposed this patient to frank hyperkalemia with progressive dehydration and slightly reduced renal function during antihypertensive therapy." | ( Azukizawa, S; Kaneko, M; Kigoshi, T; Matsui, A; Morimoto, S; Nakano, S; Uchida, K, 1994) |
| "A retrospective review of patients with primary hyperaldosteronism treated at the Duke University Medical Center was performed." | ( Gunnells, JC; Leight, GS; Weigel, RJ; Wells, SA, 1994) |
| "The major etiologies of primary aldosteronism are aldosterone-producing adrenal adenoma, requiring a surgical treatment, and bilateral hyperplasia, usually managed with medical therapy." | ( Abram, M; Charbonnel, B; Chatal, JF; Chupin, M; Dupas, B; Gaillard, F; Murat, A; Peltier, P, 1993) |
| "Since detection of familial hyperaldosteronism type I (glucocorticoid-suppressible hyperaldosteronism) allows specific treatment of hypertension with dexamethasone, we compared clinical, biochemical and genetic approaches to detection." | ( Bachmann, AW; Gordon, RD; Jonsson, JR; Klemm, SA; Stowasser, M; Tunny, TJ, 1995) |
| "In the 13 patients with Conn's syndrome, the same hemodynamic parameters were studied in 13 after drug therapy using spironolactone and in 8 after surgery." | ( Amah, G; Ben Maiz, H; Blacher, J; Girerd, X; Kheder, A; Safar, M, 1997) |
| "In familial hyperaldosteronism type I (FH-I), glucocorticoid treatment suppresses adrenocorticotrophic hormone-regulated hybrid gene expression and corrects hyperaldosteronism." | ( Gartside, MG; Gordon, RD; Stowasser, M; Taylor, WL; Tunny, TJ, 1997) |
| "Primary aldosteronism, though an uncommon cause of hypertension, causes significant morbidity, making it important to diagnose and treat this condition." | ( Eng, PH; Fok, AC; Ho, SC; Khoo, DH; Koh, LK; Lim, HS; Lim, SC; Tai, ES; Tan, CE; Tan, KE, 1997) |
| "Primary aldosteronism was confirmed with the determination of PAC after 2 L saline administered iv over 4 h." | ( Emmanuel, SC; Khaw, MC; Koay, ES; Loh, KC; Young, WF, 2000) |
| "Thus, retroperitoneoscopic treatment of Conn's syndrome should not be carried out unless venous sampling is carried out first." | ( Brockmann, J; Cromme, S; Glodny, B; Kühle, C; Winde, G, 2000) |
| "Specific treatment of primary aldosteronism (adrenalectomy, treatment with spironolactone) led to the normalization of the BP curve with a marked BP decline." | ( Widimský, J; Zelinka, T, 2001) |
| "When primary aldosteronism is diagnosed, fewer than one-third of patients are suitable for surgery as initial treatment, but this still represents a significant percentage of hypertensive patients." | ( Gordon, RD; Rutherford, JC; Stowasser, M, 2001) |
| "In patients with primary aldosteronism treated with spironolactone (n = 8), renin escaped suppression and reached very high levels." | ( Hahn, EG; Hensen, J; Schobel, H; Seifarth, C; Trenkel, S, 2002) |
| "Primary aldosteronism is a specifically treatable and potentially curable form of secondary hypertension." | ( Chiandussi, L; Milan, A; Morello, F; Mulatero, P; Paglieri, C; Rabbia, F; Veglio, F, 2002) |
| "The incidence of primary aldosteronism in patients with difficult to treat hypertension is higher than previously stated in texts." | ( Guertler, M; Suter, PM; Vetter, W, 2003) |
| "A 68-year-old male with primary aldosteronism who was scheduled for electroconvulsive therapy (ECT)." | ( Hamaguchi, S; Kimura, Y; Kitajima, T; Nagao, M; Okuda, Y; Takanishi, T; Tezuka, M; Wake, K, 2003) |
| "Once considered rare, primary aldosteronism (PAL) is now regarded as the commonest potentially curable and specifically treatable form of hypertension." | ( Gordon, RD; Stowasser, M, 2004) |
| "To examine the role of hyperaldosteronism, we also evaluated rats treated with a sodium-deficient diet or subcutaneous aldosterone infusion." | ( Fukushima, K; Funayama, Y; Krozowski, Z; Naito, H; Sasaki, I; Sasano, H; Sato, S; Shibata, C; Suzuki, T, 2005) |
| "A total of 92 patients with primary hyperaldosteronism were laparoscopically treated at our institution from 1995 to 2004." | ( Arai, Y; Chiba, Y; Ishidoya, S; Ito, A; Sakai, K; Sato, F; Satoh, M, 2005) |
| "In rats with aldosteronism, cotreatment with Hctz+Spi more effectively (vis-à-vis Hctz alone) protects against adverse iterations in extracellular and intracellular concentrations of Ca2+ and Mg2+, as well as the appearance of oxi/nitrosative stress to prevent the proinflammatory vascular phenotype." | ( Ahokas, RA; Bhattacharya, SK; Chhokar, VS; Gerling, IC; Runyan, AL; Sun, Y; Weber, KT, 2005) |
| "Primary hyperaldosteronism is a frequently neglected cause of residual hypertension despite technically successful endovascular treatment of renal artery disease." | ( Corrocher, R; Girelli, D; Guarini, P; Olivieri, O; Pavan, C; Pizzolo, F; Trabetti, E, 2005) |
| "Primary hyperaldosteronism due to APA was associated with normal circadian BP variability and the surgical treatment led to highly significant decline in all BP parameters but had no influence on the extent of nocturnal BP variation." | ( Elenkova, A; Kalinov, K; Nachev, E; Orbetzova, M; Schigarminova, R; Stoynev, A; Yaneva, M; Zacharieva, S, 2006) |
| "Treatment of primary aldosteronism decreased blood pressure significantly, and during the initial 6 months of follow-up, parameters of insulin sensitivity were restored to normal." | ( Baroselli, S; Catena, C; Cavarape, A; Colussi, G; Favret, G; Lapenna, R; Melis, A; Nadalini, E; Novello, M; Sechi, LA, 2006) |
| "Surgically correctable forms of primary aldosteronism are generally held to be less common than forms requiring medical therapy." | ( Rossi, GP, 2006) |
| "In the case report survey, pseudoaldosteronism developed a median 35 (range 2-231) days after the administration of SKT, which is shorter than after SST (450, range 150-2190 days) and other licorice products including glycyrrhizin (210, range 14-730 days)." | ( Homma, M; Ishihara, M; Kohda, Y; Qian, W, 2006) |
| "Treatment of primary aldosteronism decreased blood pressure (BP) and restored normal potassium concentrations." | ( Baroselli, S; Bazzocchi, M; Catena, C; Chiuch, A; Colussi, GL; Lapenna, R; Nadalini, E; Novello, M; Sechi, LA, 2007) |
| "Patients with primary aldosteronism were compared with patients with essential hypertension and were treated to reach a blood pressure of less than 140/90 mm Hg." | ( Baroselli, S; Catena, C; Chiuch, A; Colussi, G; Lapenna, R; Nadalini, E; Sechi, LA, 2008) |
| "Primary aldosteronism is associated with a cardiovascular complication rate out of proportion to blood pressure levels that benefits substantially from surgical and medical treatment in the long term." | ( Baroselli, S; Catena, C; Chiuch, A; Colussi, G; Lapenna, R; Nadalini, E; Sechi, LA, 2008) |
| "The pseudohyperaldosteronism in this case was caused by the administration of a traditional Chinese medicine, which contained 2." | ( Abe, M; Abe, T; Ito, S; Tanemoto, M; Toyohara, T; Uruno, A, 2008) |
| "Diagnosis of primary hyperaldosteronism was further confirmed by the response to treatment with spironolactone." | ( Douma, S; Doumas, M; Kartali, N; Papadopoulos, N; Papaefthimiou, P; Petidis, K; Triantafyllou, A; Vogiatzis, K; Zamboulis, C, 2008) |
| "We report a case of obvious pseudoaldosteronism which occurred after the additional administration of cilostazol against arteriosclerosis obliterans (ASO) for bilateral legs in a 65 year-old man patient who had safely received glycyrrhizin for the previous ten years." | ( Aoyagi, M; Inaba, N; Maeda, Y; Shiigai, T; Tanase, T, 2008) |
| "Recent data suggest that primary aldosteronism is found in about 10% of hypertensive patients managed in primary care and diagnosed in about 20% of treated but uncontrolled hypertensive patients." | ( Girerd, X, 2008) |
| "Surgical treatment of primary hyperaldosteronism (PHA) requires demonstration of unilateral adrenal hypersecretion." | ( Cho, KJ; Doherty, GM; Gauger, PG; Hammer, GD; Miller, BS; Thompson, NW; White, ML, 2008) |
| "To determine the prevalence of primary hyperaldosteronism in hypertensive patients treated at the hypertension league of a university hospital." | ( Faria, Mdos S; Figueiredo Neto, JA; Lopes, Mde C; Memória, EV; Oliveira, TC; Ribeiro, MJ; Salgado Filho, N, 2009) |
| "During the last two decades, primary aldosteronism has emerged as the most common cause of secondary hypertension, and advances in the diagnosis and treatment of this condition have improved patient care substantially." | ( Anderson, ME; Auchus, RJ; Chan, D; Dolmatch, BL; Josephs, SC; Nwariaku, FE; Toomay, S; Trimmer, CK; Wians, FH, 2010) |
| "Clinically, treating primary aldosteronism patients decreased MDA and PINP levels." | ( Becerra, E; Carvajal, CA; Fardella, CE; García, L; Jalil, J; Lavandero, S; Mellado, R; Mosso, L; Ocaranza, MP; Solis, M; Stehr, CB, 2010) |
| "Treating primary aldosteronism patients reduced MDA and PINP levels, which may reflect the direct effect of aldosterone greater than endothelial oxidative stress and myocardial fibrosis, possibly mediated by a mineralocorticoid receptor." | ( Becerra, E; Carvajal, CA; Fardella, CE; García, L; Jalil, J; Lavandero, S; Mellado, R; Mosso, L; Ocaranza, MP; Solis, M; Stehr, CB, 2010) |
| "In patients with primary hyperaldosteronism, distinguishing between unilateral and bilateral adrenal hypersecretion is critical in assessing treatment options." | ( Alexander, HR; Ayala, A; Baid, S; Chang, RE; Dutta, U; Hughes, M; Kebebew, E; Kemp, CD; Lange, E; Libutti, SK; Linehan, WM; Mathur, A; Papademetriou, V; Phan, GQ; Pingpank, JF; Pinto, PA; Steinberg, SM; Stratakis, CA, 2010) |
| "Because primary aldosteronism is not uncommon, specifically treatable and in some cases curable, and carries higher risks for cardiovascular morbidity and mortality than essential hypertension, screening hypertensive patients for its presence by measuring aldosterone to renin ratio (ARR) is increasingly common." | ( Ahmed, AH; Gordon, RD; Pimenta, E; Stowasser, M; Taylor, PJ; Ward, G, 2011) |
| "To evaluate the prevalence of primary aldosteronism (PA) in newly diagnosed and untreated hypertensive patients in primary care using the aldosterone/renin ratio (ARR), and to assess clinical and biochemical characteristics in patients with high and normal ARR." | ( Bergenfelz, A; Isaksson, A; Nerbrand, C; Valdemarsson, S; Westerdahl, C, 2011) |
| "In most cases of primary aldosteronism (PA), An adrenal aldosterone-secreting tumor cannot be reasonably proven, so these patients undergo medical treatment." | ( Benso, A; Capello, E; Caprino, MP; Ghigo, E; Lucatello, B; Maccario, M; Marafetti, L; Oleandri, SE; Rossato, D; Tabaro, I, 2013) |
| "In primary aldosteronism (PA), lateralized aldosterone excess can be treated with aldosterone antagonists or surgery, which raises the question as to whether surgery or medications should be the preferred management." | ( Dias, VC; Harvey, A; Kline, GA; Pasieka, JL; So, B, 2013) |
| "Hyperaldosteronism due to klotho deficiency results in vascular calcification, which can be mitigated by spironolactone treatment." | ( Fahrleitner-Pammer, A; Gaksch, M; Grübler, M; Kienreich, K; Kraigher-Krainer, E; März, W; Mrak, P; Pieske, B; Pilz, S; Ritz, E; Rus-Machan, J; Tomaschitz, A; Toplak, H; Verheyen, N, 2014) |
| "Refractory hyperaldosteronism is frequently observed in heart failure patients on up-to-date treatment, and holds prognostic value." | ( Abbate, R; Emdin, M; Fatini, C; Gensini, G; Passino, C; Ripoli, A; Rossignol, P; Sticchi, E; Vassalle, C; Vergaro, G, 2015) |
| "Primary aldosteronism (PA) is a condition well worth detecting because it is a common cause of hypertension and is associated with excessive morbidity for the degree of hypertension and reduced quality of life, all of which can be abrogated with specific surgical or medical treatment." | ( Stowasser, M, 2015) |
| "Primary aldosteronism is one of the commonly identified causes of hypertension and is treatable and/or potentially curable." | ( Ardhanari, S; Chaudhary, K; Kannuswamy, R; Lockette, W; Whaley-Connell, A, 2015) |
| "Primary aldosteronism (PA) is present in up to 20% of patients with treatment-resistant hypertension (TRH)." | ( Arbique, D; Brinker, S; Chung, O; Das, SR; Lotan, Y; Pandey, A; Price, A; Raza, F; Velasco, A; Vongpatanasin, W, 2015) |
| "Primary hyperaldosteronism is a specifically treatable and potentially curable form of hypertension, which typically presents as drug-resistant hypertension and, in up to 37% of cases, hypokalemia." | ( Fong, BM; Siu, TS; Tam, S, 2015) |
| "Primary aldosteronism is one of the most common forms of secondary hypertension, but it is often under diagnosed, which leads to the development of cardiovascular damage, and excess costs for long-term drug treatment and management of complications." | ( Bisogni, V; Rossi, GP, 2016) |
| "Treatment of primary aldosteronism (PA) aims at preventing or correcting hypertension, hypokalemia and target organ damage." | ( Amar, L; Chaffanjon, P; Kraimps, JL; Ménégaux, F; Steichen, O; Zinzindohoue, F, 2016) |
| "Once thought to be rare, primary aldosteronism (PA, in which aldosterone secretion by the adrenal is excessive and autonomous of its principal regulator, angiotensin II) is now known to be the most common specifically treatable and potentially curable form of hypertension, with most patients lacking the clinical feature of hypokalemia, the presence of which was previously considered to be necessary to warrant further efforts towards confirming a diagnosis of PA." | ( Gordon, RD; Stowasser, M, 2016) |
| "Longstanding primary aldosteronism (PA) has deleterious effects on renal function, often masked until treatment (adrenalectomy or spironolactone) is initiated." | ( Deinum, J; Kramers, BJ; Kramers, C; Lenders, JW, 2017) |
| "The treatment goal for primary aldosteronism is not only to cure the hypertension but also to prevent organ disorders due to inappropriate aldosterone levels." | ( Ichikawa, T; Imamoto, T; Kaga, M; Kamiya, N; Kawamura, K; Kono, T; Nagano, H; Namekawa, T; Suzuki, H; Tanaka, T; Utsumi, T, 2017) |
| "OSA is common in patients with primary aldosteronism and may improve with specific therapy for this disease." | ( Calhoun, D; Cowley, D; Gordon, RD; Pimenta, E; Stowasser, M; Wolley, MJ, 2017) |
| "Primary aldosteronism (PA) is the most common form of secondary hypertension and is critical to identify because when caused by an aldosterone-producing adenoma (APA) or another unilateral form, it is potentially curable, and even when caused by bilateral disease, antihypertensives more specific to PA treatment can be employed (ie, aldosterone antagonists)." | ( Holmes, DT; Kline, G, 2017) |
| "Untreated patients with primary aldosteronism showed an impaired physical and mental HRQoL as compared to the general population." | ( Burgers, VWG; de Nooijer, AH; Deinum, J; Hermus, ARMM; Husson, O; Lenders, JWM; Timmers, HJLM; Velema, MS, 2017) |
| "Primary aldosteronism (PA) significantly increases the risk of cardiovascular complications, and early diagnosis and targeted treatment based on its pathophysiology is warranted." | ( Omata, K; Rainey, WE; Tomlins, SA, 2017) |
| "Primary aldosteronism causes hypertension and hypokalemia and is often surgically treatable." | ( Berber, E; Jin, J; Kahramangil, B; Krishnamurthy, V; Monteiro, R; Shin, J; Siperstein, A; Swearingen, AJ, 2018) |
| "Cases of primary aldosteronism associated with CLCN2 mutations appear to be bilateral and respond well to medical treatment." | ( Gordon, RD; Schewe, J; Scholl, UI; Stölting, G; Stowasser, M; Wolley, M; Wu, A, 2019) |
| "Our findings suggest that in primary aldosteronism patients to whom DAPD were administrated due to severe clinical features, laterality index more than 4 in ACTH-AVS could accurately predict a biochemical cure after adrenalectomy." | ( Akasaka, H; Fujii, Y; Fujita, M; Ichijo, T; Inagaki, N; Itoh, H; Kamemura, K; Katabami, T; Kawamura, T; Kawashima, J; Kobayashi, H; Kurihara, I; Matsuda, Y; Miyauchi, S; Nagasawa, M; Naruse, M; Ogawa, Y; Ogo, A; Okamura, S; Otsuki, M; Rakugi, H; Shibata, H; Shibayama, Y; Sone, M; Suzuki, T; Takahashi, K; Takeda, M; Takeda, Y; Tsuiki, M; Umakoshi, H; Wada, N; Watanabe, M; Yamamoto, K; Yanase, T; Yoshimoto, T, 2019) |
| "Current clinical guidelines of primary aldosteronism recommend adrenalectomy (AdX) for unilateral primary aldosteronism based on the studies showing the potential superiority of AdX over the medical treatment." | ( Fujii, Y; Fujita, M; Fukuda, H; Ichijo, T; Inagaki, N; Ito, H; Kamemura, K; Katabami, T; Kawashima, J; Kobayashi, H; Kurihara, I; Matsuda, Y; Naruse, M; Ogawa, Y; Ogo, A; Otsuki, M; Shibata, H; Shibayama, Y; Sone, M; Suzuki, T; Takahashi, K; Takeda, Y; Tanaka, Y; Tsuiki, M; Tsukiyama, H; Wada, N; Watanabe, M; Yamamoto, K; Yanase, T; Yoshimoto, T, 2019) |
| "In patients with primary aldosteronism, specific treatment provides prognostic benefit over optimal antihypertensive therapy and is therefore crucial to reduce mortality and morbidity in this subgroup of patients with hypertension." | ( Adolf, C; Beuschlein, F; Heinrich, D; Holler, F; Lechner, B; Lechner, K; Reincke, M; Schneider, H, 2019) |
| "Following primary aldosteronism treatment, after a median follow-up of 12 months, a reduction in eGFR was observed [by -10." | ( Buffolo, F; D'Ascenzo, F; Monticone, S; Mulatero, P; Satoh, F; Sconfienza, E; Sechi, LA; Veglio, F, 2020) |
| "Patients affected by primary aldosteronism, compared with patients affected by arterial hypertension without primary aldosteronism, display a more pronounced target organ damage, which can be mitigated by the specific treatment." | ( Buffolo, F; D'Ascenzo, F; Monticone, S; Mulatero, P; Satoh, F; Sconfienza, E; Sechi, LA; Veglio, F, 2020) |
| "Primary aldosteronism (PA) is mainly treated by mineralocorticoid receptor antagonists or laparoscopic adrenalectomy (LA), but the effectiveness of surgical versus medical treatment in patients with adrenal venous sampling (AVS)-proven unilateral PA is unclear." | ( Cai, J; Fan, P; Jiang, XJ; Lou, Y; Lu, PP; Ma, WJ; Meng, X; Song, L; Wu, HY; Zhang, HM; Zhang, Y; Zhou, XL, 2020) |
| "Accurate subtyping of the primary aldosteronism into aldosterone-producing adenoma (APA) and idiopathic adrenal hyperplasia (IAH) is important to direct for specific treatment modalities." | ( Chan, KW; Fong, CHY; Lau, EYF; Leung, HT; Leung, JYY; Tan, KCB; Woo, YC, 2020) |
| "Primary aldosteronism (PA) is characterized by excess production of aldosterone from the adrenal glands and is the most common and treatable cause of secondary hypertension." | ( Chen, ZW; Chou, CH; Hung, CS; Liao, CW; Lin, YH; Pan, CT; Tsai, CH; Wu, VC, 2019) |
| "Primary aldosteronism is currently considered to represent 5-13% of hypertension, yet fewer than 1% of patients with the disorder are ever diagnosed and treated." | ( Funder, J, 2020) |
| "Primary aldosteronism (PA) due to unilateral aldosterone-producing adenoma (APA) is preferentially treated by unilateral adrenalectomy (ADX), but little is known about the changes in lipid and glucose metabolism that may occur after ADX." | ( Adolf, C; Berends, AMA; Connelly, MA; Dullaart, RPF; Reincke, M, 2020) |
| "After the treatment of primary aldosteronism, glucose intolerance was improved in 66." | ( Fukuda, I; Moriya, A; Nagao, M; Oikawa, S; Okazaki-Hada, M; Sugihara, H, 2020) |
| "In addition, primary aldosteronism treatments can ameliorate glucose intolerance more effectively in patients without obesity and/or central obesity." | ( Fukuda, I; Moriya, A; Nagao, M; Oikawa, S; Okazaki-Hada, M; Sugihara, H, 2020) |
| "Primary aldosteronism (PA) is the most common cause of secondary hypertension, and a simpler non-invasive method for identification of aldosterone-producing adenoma (APA) is required to improve the standard of medical treatment for PA patients." | ( Chen, S; Liu, H; Luo, P; Yu, Y, 2021) |
| "Primary aldosteronism (PA) is the most common reason of secondary hypertension, that can be cured surgically or treated with targeting medical treatment." | ( Balutina, OV; Beltsevich, DG; Ladygina, DO; Young, W, 2020) |
| "Primary aldosteronism (PA) patients diagnosed with aldosterone-producing adenoma and unilateral adrenal hyperplasia are preferred for surgical treatment." | ( Liu, G; Luo, GH, 2021) |
| "After confirmation of Conn's syndrome a differentiation between a unilateral and bilateral adrenal disease is necessary for further treatment planning." | ( Adolf, C; Fuss, CT; Hahner, S; Heinrich, DA, 2022) |
| "Targeted treatment of primary aldosteronism (PA) is informed by adrenal vein sampling (AVS), which remains limited to specialized centers." | ( Caughlin, CE; Chin, A; Harvey, A; Hundemer, GL; Kline, GA; Leung, AA; Pasieka, JL; Przybojewski, SJ; Sam, D; So, B, 2022) |
| "Primary aldosteronism (PA) is the most common cause of endocrine hypertension and adrenalectomy is the firstline treatment for unilateral PA." | ( Andreassen, M; Clausen, C; Feltoft, CL; Krogh, J; Mørup, S; Voss, N, 2022) |
| "To assess the identification of primary aldosteronism (PA) in newly diagnosed, treatment-naïve patients with hypertension by screening in primary care." | ( Fuller, PJ; Gwini, SM; Libianto, R; Nuttall, P; Russell, GM; Shen, J; Stowasser, M; Yang, J; Young, MJ, 2022) |
| "In patients with primary aldosteronism, adrenalectomy or treatment with mineralocorticoid receptor antagonists significantly mitigate adverse aldosterone effects, reducing the risk of cardiovascular events, mortality, and incident atrial fibrillation." | ( Buffolo, F; Monticone, S; Mulatero, P; Tetti, M, 2022) |
| "Primary aldosteronism affects up to 10% of hypertensive patients and is responsible for treatment resistance and increased cardiovascular risk." | ( Abdellatif, AB; Amar, L; Baron, S; Beuschlein, F; Boulkroun, S; Chantalat, S; Cosentino, T; Cusi, D; De Sousa, K; Deleuze, JF; Deschasaux, M; Druesne-Pecollo, N; Empana, JP; Ferey, M; Fernandes-Rosa, FL; Frouin, A; Gieger, C; Giscos-Douriez, I; Jeunemaitre, X; Jouven, X; Larsen, CK; Le Floch, E; Lenzini, L; Meatchi, T; Meneton, P; Peters, A; Reincke, M; Rossi, GP; Saintpierre, B; Salvi, E; Touvier, M; Waldenberger, M; Zennaro, MC, 2022) |
| "Appropriate treatment of primary aldosteronism (PA) depends on accurate lateralization." | ( Chang, CC; Chen, CJ; Chueh, JS; Lu, CC; Peng, KY; Wu, VC; Yen, RF, 2022) |
| "Patients with primary aldosteronism (PA) tend to exhibit a high prevalence of osteoporosis (OP) that may vary by whether PA is unilateral or bilateral, and responsive to PA treatment." | ( Hu, X; Li, J; Liu, H; Lyu, Z; Nie, Z; Wang, A; Wang, Y; Xu, H; Zhang, L, 2022) |
| "Patients with primary aldosteronism (PA) tend to exhibit a high prevalence of osteoporosis (OP) that may vary by whether PA is unilateral or bilateral, and responsive to PA treatment." | ( Hu, X; Li, J; Liu, H; Lyu, Z; Nie, Z; Wang, A; Wang, Y; Xu, H; Zhang, L, 2022) |
| "Patients with primary aldosteronism (PA) tend to exhibit a high prevalence of osteoporosis (OP) that may vary by whether PA is unilateral or bilateral, and responsive to PA treatment." | ( Hu, X; Li, J; Liu, H; Lyu, Z; Nie, Z; Wang, A; Wang, Y; Xu, H; Zhang, L, 2022) |
| "Primary aldosteronism (PA), a typical form of secondary hypertension, is responsible for treatment-resistant hypertension and carries an even higher risk of causing cardiovascular complications than essential hypertension." | ( Itoh, H; Kurihara, I; Shibata, H; Sone, M; Yokota, K, 2023) |
| "Primary aldosteronism (PA), a typical form of secondary hypertension, is responsible for treatment-resistant hypertension and carries an even higher risk of causing cardiovascular complications than essential hypertension." | ( Itoh, H; Kurihara, I; Shibata, H; Sone, M; Yokota, K, 2023) |
| "Primary aldosteronism (PA), characterised by low-renin hypertension, confers a high cardiovascular risk and is the most common cause of secondary hypertension, with an increased prevalence in patients with treatment-resistant hypertension." | ( Beger, C; Haller, H; Hinrichs, JB; Karg, T; Limbourg, FP; Meyer, BC; Ringe, B, 2023) |
| "The diagnosis and treatment of primary aldosteronism is of paramount significance, since depending on its subtype, surgical or pharmaceutical intervention can lead to the full recovery of the patient." | ( Igaz, P; Vékony, B, 2023) |
| "Patients with bilateral primary aldosteronism (PA) generally are treated with antihypertensive drugs, but optimal treatment for patients with complications due to refractory hypertension has not been established." | ( Akaihata, H; Hata, J; Honda-Takinami, R; Hoshi, S; Kataoka, M; Kojima, Y; Matsuoka, K; Ogawa, S; Onagi, A; Sato, Y; Tanji, R, 2023) |
| "If the diagnostic test of primary aldosteronism is positive, but the treatment with spironolactone is ineffective, we should actively search for other causes." | ( Pan, R; Wang, R; Zhang, R; Zhang, Y; Zhao, Y, 2023) |